open access

Vol 5, Supp. A (2009)
suplement
Published online: 2009-04-29
Get Citation

Antiangiogenic treatment of ovarian cancer patients

Marek Z. Wojtukiewicz, Ewa Sierko, Paweł Szambora

open access

Vol 5, Supp. A (2009)
suplement
Published online: 2009-04-29

Abstract

According to 2007 American Cancer Society statistics, ovarian cancer is recognized as the most lethal gynecologic cancer. Standard treatment includes surgery and chemotherapy based on platinum derivatives and taxanes. However, treatment outcomes are not satisfactory because most patients develope cytostatic treatment resistant progressive disease. Searching for new strategies for ovarian cancer patients is thus warranted. Angiogenesis is one of the most important mechanisms responsible for cancer progression, while it is important in ovarian physiology as well. This review highlights the results of the latest clinical studies of antiangiogenic agents in ovarian cancer and discusses the perspectives for future clinical trials.

Abstract

According to 2007 American Cancer Society statistics, ovarian cancer is recognized as the most lethal gynecologic cancer. Standard treatment includes surgery and chemotherapy based on platinum derivatives and taxanes. However, treatment outcomes are not satisfactory because most patients develope cytostatic treatment resistant progressive disease. Searching for new strategies for ovarian cancer patients is thus warranted. Angiogenesis is one of the most important mechanisms responsible for cancer progression, while it is important in ovarian physiology as well. This review highlights the results of the latest clinical studies of antiangiogenic agents in ovarian cancer and discusses the perspectives for future clinical trials.
Get Citation

Keywords

ovarian cancer; angiogenesis; bevacizumab

About this article
Title

Antiangiogenic treatment of ovarian cancer patients

Journal

Oncology in Clinical Practice

Issue

Vol 5, Supp. A (2009)

Pages

39-43

Published online

2009-04-29

Keywords

ovarian cancer
angiogenesis
bevacizumab

Authors

Marek Z. Wojtukiewicz
Ewa Sierko
Paweł Szambora

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl